TEMIS Acquires i3 Analytics

News provided by

Jun 27, 2013, 08:00 ET

PARIS and COLUMBIA, Maryland, June 27, 2013 /PRNewswire/ --

TEMIS complements leading-edge Luxid® semantic content enrichment platform
with best-in-class data analytics and visualization capabilities.

TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced today that they have acquired the US-based i3 Analytics, a provider of advanced data analytics and visualization technologies, for an undisclosed amount.

Founded in 2011 and employing former NIH (National Institutes of Health) engineers, i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data. Providing customers with tailor-made, relevant and intuitive visualization maps, the i3 Analytics' Biopharma Navigator enables Life Sciences professionals to work faster, provide critical information to their peers, and make fast and informed clinical, regulatory, and business decisions.

Awarded "Best Semantic Technology Solution" in January 2013 by the Software and Information Industry Association (SIIA) for its flagship platform Luxid®, TEMIS has developed an in-depth expertise serving the information extraction and semantic enrichment needs of a varied range of industries, including Defence, Publishing & Media, as well as Life Sciences, where demand for easy-to-use, intuitive visualization and analytics tools has been growing in step with the exponential growth of available unstructured content. This acquisition reinforces TEMIS' commitment and capabilities to serving its customers by strengthening its product range with a complementary SaaS Analytics and Discovery offering and expanding its know-how with the integration of a team of former NIH engineers. The acquisition will also enable TEMIS to accelerate its penetration into new application areas in Life Sciences.

"The acquisition of i3 Analytics demonstrates our commitment to the Life Sciences market", said Eric Brégand, CEO of TEMIS. "This transaction creates a best-in-class offering for our Life Sciences customers, based on the winning combination of deep computational linguistics expertise and leading-edge data visualization know-how. And we will be transposing the solution to other verticals where data analytics and information visualization are also becoming critical."

Moving forward, and with a focus on maintaining its commitment to simplicity and innovation, TEMIS will integrate the SaaS Biopharma Navigator into its Luxid® product line and make it available for other application segments.

About TEMIS

TEMIS helps organizations structure, manage and leverage their unstructured information assets. Its flagship platform, Luxid®, identifies and extracts targeted information to semantically enrich content with domain-specific metadata. Luxid® enables professional publishers to efficiently package and deliver relevant information to their audience, and helps enterprises to intelligently archive, manage, analyze, discover and share increasing volumes of information.

Founded in 2000, TEMIS operates in the United States, Canada, UK, France and Germany, and is represented worldwide through its network of certified partners.

TEMIS' innovative solutions have attracted the business of leading organizations such as AAAS (American Association for the Advancement of Science), Agence France-Presse, BASF, Bayer Pharma, Bloomberg BNA, BNP Paribas, Editions Lefebvre-Sarrut, Elsevier, EMC, Europol, French Ministry of Defence, French Ministry of Finance, Gannett, Karger, Invest in France Agency, Les Echos, Merck KGaA, Nature Publishing Group, Novartis, Philip Morris International, PSA Peugeot-Citroën, Sanofi, Simon & Schuster, Springer Science+Business Media, The McGraw-Hill Companies, Thieme, Thomson Reuters, the U.S. Department of Agriculture, Volkswagen and Wiley.

http://www.temis.com
http://tagline.temis.com

SOURCE TEMIS